Limitations of Personalized Medicine and Gene Assays for Breast Cancer

Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local treatment of primary stage I-III breast cancers. For patients with hormone-positive breast cancers receiving hormonal therapy, the risk of distant recurrence is under 20% and therefore, many patients may pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiberi, David, Masucci, Laura, Shedid, Daniel, Roy, Isabelle, Vu, Toni, Patocskai, Erica, Robidoux, André, Wong, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393908/
https://www.ncbi.nlm.nih.gov/pubmed/28428927
http://dx.doi.org/10.7759/cureus.1100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393908/
https://www.ncbi.nlm.nih.gov/pubmed/28428927
http://dx.doi.org/10.7759/cureus.1100

Ejemplares similares